Agenus reports Q4 EPS ($2.04), consensus ($2.54)

Reports Q4 revenue $26.84M, consensus $30.09M. “In line with our strategic objectives, we significantly reduced our annualized operational burn rate. We anticipate further reducing our annual burn to an annualized rate of approximately $50 million by mid-2025 through the externalization of development costs associated with BOT/BAL, monetization of our CMC assets, and other reductions in operating expenses,” stated Garo Armen, chairman and CEO of Agenus (AGEN). “These steps reflect our commitment to prioritizing resources for BOT/BAL- our most promising clinical asset- while maintaining its development trajectory.”